Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
University of Rochester NCORP Research Base
Recruiting ID
For more information, see NCT03367572
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Breast Carcinoma
Luke Peppone, Bryan A. Faller, Brian L. Burnette, Site Public Contact, Mary Ontko, Eileen Mederos, RN, Kamara Mertz-Rivera, Connie Szczepanek, RN, Amy Koffarnus, Neha Glandt, Kristina Gardner, Heather Albertson, Sheree Oxley, Kin Williams, Sarah Smith, Susan Tuttle, Karen Sartell, Kate Bryant-Greenwood, Debbie Kettner-Sieber, Jenna Russell

See list of participating sites